Novel/JJ
therapies/NNS
for/IN
inflammatory/JJ
bowel/NN
disease/NN
./.

Looking/VBG
back/RB
at/IN
successes/NNS
and/CC
failures/NNS
in/IN
newer/JJR
approaches/NNS
to/TO
treating/VBG
IBD/NN
,/,
it/PRP
is/VBZ
tempting/JJ
--/:
although/IN
still/RB
difficult/JJ
--/:
to/TO
draw/VB
conclusions/NNS
about/IN
pathogenesis/NN
./.
=====
When/WRB
a/DT
therapy/NN
proves/VBZ
effective/JJ
,/,
do/VBP
clinicians/NNS
truly/RB
know/VB
how/WRB
it/PRP
works/VBZ
?/.
Even/RB
with/IN
a/DT
therapy/NN
as/IN
specific/JJ
as/IN
anti-TNF/JJ
antibody/NN
,/,
it/PRP
is/VBZ
not/RB
clear/JJ
if/IN
the/DT
benefit/NN
is/VBZ
attributable/JJ
to/TO
simple/JJ
binding/NN
and/CC
clearance/NN
of/IN
TNF-alpha/NN
or/CC
to/TO
binding/NN
on/IN
the/DT
cell/NN
surface/NN
and/CC
subsequent/JJ
deletion/NN
of/IN
the/DT
activated/VBN
macrophage/NN
./.
=====
When/WRB
a/DT
drug/NN
appears/VBZ
to/TO
be/VB
less/RBR
effective/JJ
than/IN
preclinical/JJ
models/NNS
suggest/VBP
,/,
can/MD
failures/NNS
in/IN
effectiveness/NN
from/IN
delivery/NN
or/CC
dosing/NN
be/VB
differentiated/VBN
?/.
The/DT
disappointing/JJ
results/NNS
of/IN
clinical/JJ
trials/NNS
with/IN
IL-10/NN
--/:
so/RB
at/IN
odds/NNS
with/IN
the/DT
prediction/NN
of/IN
benefit/NN
from/IN
animal/NN
models/NNS
--/:
bring/VBP
into/IN
question/NN
the/DT
validity/NN
of/IN
those/DT
models/NNS
as/RB
well/RB
as/IN
the/DT
soundness/NN
of/IN
design/NN
of/IN
the/DT
clinical/JJ
trials/NNS
on/IN
which/WDT
efficacy/NN
of/IN
IL-10/NN
is/VBZ
judged/VBN
./.
=====
The/DT
variability/NN
of/IN
response/NN
even/RB
to/TO
the/DT
most/RBS
narrowly/RB
targeted/VBN
agents/NNS
suggests/VBZ
that/IN
these/DT
diseases/NNS
are/VBP
far/RB
more/RBR
heterogeneous/JJ
in/IN
humans/NNS
than/IN
in/IN
their/PRP$
murine/JJ
counterparts/NNS
./.
=====
Clinicians/NNS
are/VBP
only/RB
just/RB
beginning/VBG
to/TO
recognize/VB
subclinical/JJ
markers/NNS
of/IN
response/NN
,/,
and/CC
it/PRP
may/MD
soon/RB
be/VB
possible/JJ
to/TO
predict/VB
response/NN
on/IN
the/DT
basis/NN
of/IN
genetic/JJ
composition/NN
./.
=====
For/IN
the/DT
moment/NN
,/,
however/RB
,/,
the/DT
field/NN
of/IN
pharmacogenetics/NNS
is/VBZ
embryonic/JJ
./.
=====
Challenges/NNS
in/IN
developing/VBG
new/JJ
therapeutic/JJ
strategies/NNS
include/VBP
not/RB
only/RB
identifying/VBG
novel/JJ
agents/NNS
,/,
but/CC
also/RB
improving/VBG
the/DT
definitions/NNS
of/IN
clinical/JJ
endpoints/NNS
and/CC
defining/VBG
efficacy/NN
at/IN
the/DT
biologic/JJ
level/NN
./.
=====
Only/RB
through/IN
considered/VBN
evaluation/NN
of/IN
clinical/JJ
evidence/NN
may/MD
clinicians/NNS
determine/VB
which/WDT
therapies/NNS
should/MD
remain/VB
novelties/NNS
and/CC
which/WDT
should/MD
become/VB
an/DT
accepted/VBN
part/NN
of/IN
the/DT
armamentarium/NN
./.